The Kronos CDK9 inhibitor, KB-0742, is an ultraselective inhibitor of cyclin-dependent kinase CDK9. The CDK family of kinases have been pursued as cancer drug targets for decades, but family selectivity within the highly conserved kinase family has made it difficult to identify highly selective molecules, resulting in less than ideal [...]
< 1 minute read
Feb. 9, 2022
KB-0742: an Ultraselective Inhibitor of Cyclin-Dependent Kinase CDK9
Kronos CDK9 Inhibitor
selective CDK9 inhibitor oral Ph. I candidate for MYC-amp tumors from microarray binding assay with lysate KB-0742 Kronos Bio, Cambridge, MA